Other targets Clause Samples
The "Other targets" clause defines additional objectives, benchmarks, or deliverables that are not covered by the main terms of the agreement. This clause typically outlines specific secondary goals or performance metrics that the parties agree to pursue, such as achieving certain milestones, meeting quality standards, or fulfilling supplementary obligations. By clearly identifying these extra targets, the clause ensures that all parties are aware of and accountable for these additional commitments, thereby reducing ambiguity and helping to manage expectations throughout the contractual relationship.
Other targets. Output area or initiative Target
Other targets. Output area/ initiative Target Associated Strategic Goal
Other targets. Action Associated Strategic Pillar Target Timeframe
Other targets. Subject to the terms and conditions of this Agreement, and specifically subject to the limitations set forth in Subsection 4.1.6(b) above, ArQule hereby grants to SB a nonexclusive, worldwide, royalty-free license (without the right to sublicense) under the ArQule Patent Rights and other rights in ArQule Technology to screen ArQule Compounds delivered under the collaboration against Targets in the Field other than ***** Targets and ***** Targets, but only during the Screening Phase.
Other targets. Output area/ initiative Target Timeframe Associated strategic objective
Other targets. [***], Lilly and Archemix may include [***].
Other targets. 23 2.6.3 Limitations ........................................... 23 2.7
Other targets. In the event that (i) SB fails to identify any Active Compounds from the Compass Array Library in its screens against Anti-Infective Targets and, if applicable, Anti-Fungal Targets and decides not to initiate any additional screening activities of ArQule Compounds against Anti-Infective Targets or Anti-Fungal Targets, or (ii) SB identifies fewer than [*****] Available Compounds from the Compass Array Library in its screens against Anti-Infective Targets and, if applicable, Anti-Fungal Targets, then SB may screen the unused quantities of any ArQule Compounds from the Compass Array Library retained by SB against other Targets for the duration of the Screening Phase; provided that, SB shall give ArQule written notice prior to undertaking such additional screening activities, which notice shall identify such other Targets; and, provided further that before the parties commence such activities, the parties shall negotiate in good faith the commercially reasonable financial terms pertaining to such compounds as described in Section 7.5. and 7.6. below, which terms shall be set forth in a separate agreement. In addition, if SB desires to conduct an optimization project with ArQule on any resulting Licensed Compounds, the parties shall negotiate in good faith the applicable commercially reasonable FTE rate unless the project is a substitute project as described in Subsection 4.2.6.
Other targets. Notwithstanding any other provision in this Agreement, on and after the Restatement Date, each Party and its Affiliates would be free to perform on its own any screening of Compounds against Targets other than the Collaboration Target, and any research or development of Compounds directed against Targets other than the Collaboration Target, except that such right would not include the right to:
(a) use Compounds from the other Party's Chemical Library or Compounds to which the other Party otherwise has proprietary rights,
(b) screen Compounds against the Collaboration Target except to the extent necessary to determine selectivity against Targets other than the Collaboration Target, or
(c) perform research or development on any Compound that is active against the Collaboration Target at the level that would make such a Compound a Hit. Notwithstanding the foregoing, before December 9, 2004, neither Party may collaborate on any of the activities permitted under this Section 2.6.2 with a Third Party who has been granted rights to commercialize Compounds resulting from such activities.
Other targets. In the event that (i) SB fails to identify any Active Compounds from the Compass Array Library in its screens against ***** Targets and, if applicable, ***** Targets and decides not to initiate any additional screening activities of ArQule Compounds against ***** Targets or ***** Targets, or (ii) SB identifies fewer than ***** Available Compounds from the Compass Array Library in its screens against ***** Targets and, if applicable, ***** Targets, then SB may screen the unused quantities of any ArQule Compounds from the Compass Array Library retained by SB against other Targets for the duration of the Screening Phase; provided that, SB shall give ArQule written notice prior to undertaking such additional screening activities, which notice shall identify such other Targets; and, provided further that before the parties commence such activities, the parties shall negotiate in good faith the commercially reasonable financial terms pertaining to such compounds as described in Section 7.5. and 7.6. below, which terms shall be set forth in a separate agreement. In addition, if SB desires to conduct an optimization project with ArQule on any resulting Licensed Compounds, the parties shall negotiate in good faith the applicable commercially reasonable FTE rate unless the project is a substitute project as described in Subsection 4.2.6.